Louise Chen
Stock Analyst at Scotiabank
(4.41)
# 353
Out of 5,133 analysts
295
Total ratings
48.07%
Success rate
22.01%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $55.92 | +7.30% | 2 | Jan 9, 2026 | |
| TEVA Teva Pharmaceutical Industries | Initiates: Sector Outperform | $35 | $32.47 | +7.79% | 4 | Dec 5, 2025 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $108.26 | +10.84% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $758.91 | +1.46% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $21.46 | +272.79% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $2.71 | +232.10% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $24.95 | -43.89% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $2.23 | +438.12% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $19.51 | +181.91% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $75.40 | -27.06% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $2.51 | +497.61% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $103.54 | -51.71% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $7.04 | +113.07% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $35.28 | -51.81% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $72.43 | -3.35% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $17.04 | +193.43% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $11.31 | +165.25% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $18.72 | +193.80% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.45 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $59.64 | +168.28% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $46.02 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $220.75 | +8.72% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.15 | +78.93% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $213.65 | +0.63% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.92 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $23.44 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,077.19 | -17.84% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.72 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.18 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.76 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.99 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.64 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.65 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.16 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.96 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.66 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.80 | +1,610.53% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.18 | +129.36% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.95 | +234.45% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $26.05 | +91.94% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.10 | +138.10% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.57 | +1,491.79% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.69 | +244,211,187.99% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $291.77 | -11.57% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.48 | +3,278.38% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.34 | +1,398.13% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.00 | +462.50% | 1 | Jun 22, 2017 |
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $55.92
Upside: +7.30%
Teva Pharmaceutical Industries
Dec 5, 2025
Initiates: Sector Outperform
Price Target: $35
Current: $32.47
Upside: +7.79%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $108.26
Upside: +10.84%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $758.91
Upside: +1.46%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $21.46
Upside: +272.79%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $2.71
Upside: +232.10%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $24.95
Upside: -43.89%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $2.23
Upside: +438.12%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.51
Upside: +181.91%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $75.40
Upside: -27.06%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.51
Upside: +497.61%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $103.54
Upside: -51.71%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $7.04
Upside: +113.07%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $35.28
Upside: -51.81%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $72.43
Upside: -3.35%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $17.04
Upside: +193.43%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $11.31
Upside: +165.25%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.72
Upside: +193.80%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.45
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $59.64
Upside: +168.28%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $46.02
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $220.75
Upside: +8.72%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.15
Upside: +78.93%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $213.65
Upside: +0.63%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.92
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.44
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,077.19
Upside: -17.84%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.72
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.18
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.76
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.99
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.64
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.65
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.16
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.96
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.66
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.80
Upside: +1,610.53%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.18
Upside: +129.36%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.95
Upside: +234.45%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $26.05
Upside: +91.94%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.10
Upside: +138.10%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.57
Upside: +1,491.79%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.69
Upside: +244,211,187.99%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $291.77
Upside: -11.57%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.48
Upside: +3,278.38%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.34
Upside: +1,398.13%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $8.00
Upside: +462.50%